mart-1-antigen has been researched along with Adenocarcinoma-of-Lung* in 2 studies
1 review(s) available for mart-1-antigen and Adenocarcinoma-of-Lung
Article | Year |
---|---|
Malignant perivascular epithelioid cell tumor of the lung synchronous with a primary adenocarcinoma: one case report and review of the literature.
Perivascular Epithelioid Cell Tumors (PEComa) is an extraordinarily rare mesenchymal neoplasm especially the malignant type originating from the lung. To date, only 8 cases of malignant or malignant potential pulmonary PEComa had been documented. Firm diagnostic criteria for malignant pulmonary PEComa need urgently to be established.. We report a challenging case of malignant pulmonary PEComa combined with a primary adenocarcinoma in a 54-year-old man. The PEComa-like tumor showed strong Melan-A and weak transcription factor E3 (TFE3) protein expression but no TFE3 gene rearrangement. The carcinoma-like nodule was recognized as a poorly differentiated primary lung adenocarcinoma.. Our case report was the first case of malignant pulmonary PEComa synchronous with a primary adenocarcinoma and studied the dilemma of diagnosing benign versus malignant criteria for this uncommon tumor. Topics: Adenocarcinoma of Lung; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Down-Regulation; Humans; Lung Neoplasms; Male; MART-1 Antigen; Middle Aged; Neoplasms, Multiple Primary; Perivascular Epithelioid Cell Neoplasms; Pulmonary Surgical Procedures; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
1 other study(ies) available for mart-1-antigen and Adenocarcinoma-of-Lung
Article | Year |
---|---|
Melan A (A103) is not a marker of mesothelioma.
Although a large number of immunohistochemical markers have been proven to be valuable in the differential diagnosis between epithelioid mesotheliomas and metastatic carcinomas involving the serosal membrane, no single antibody has been found that is absolutely sensitive and/or specific in making this distinction. A recent study reported melan A positivity in all 12 of the epithelioid mesotheliomas stained with a melan A antibody (clone A103). To fully determine the practical value of this antibody for assisting in the differential diagnosis of mesotheliomas, we investigated the expression of melan A (A103) in 40 mesotheliomas (27 epithelioid, 6 sarcomatoid, and 7 biphasic), 10 lung adenocarcinomas, and 10 serous carcinomas of the ovary. None of the mesotheliomas, lung adenocarcinomas, or serous carcinomas of the ovary were melan A (A103) positive. Similar staining results were observed in the 20 mesotheliomas immunostained in another institution using the same antibody clone from a different commercial source. On the basis of these results, it is concluded that in contrast to the initial report, melan A (A103) is not expressed in mesotheliomas and therefore, immunostaining with this antibody has no utility in the diagnosis of mesothelioma. The possible cause of the discrepancies between the results obtained in the present investigation and those of the initial study is discussed. Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Gene Expression; Humans; Immunohistochemistry; Lung Neoplasms; MART-1 Antigen; Mesothelioma; Ovarian Neoplasms; Pleural Neoplasms; Retrospective Studies | 2013 |